中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2015年
12期
12-14
,共3页
双水平气道正压通气%舒利迭%中重度慢性阻塞性肺疾病%Ⅱ型呼吸衰竭
雙水平氣道正壓通氣%舒利迭%中重度慢性阻塞性肺疾病%Ⅱ型呼吸衰竭
쌍수평기도정압통기%서리질%중중도만성조새성폐질병%Ⅱ형호흡쇠갈
Bi-level airway pressure ventilation%Seretide%Moderate to severe chronic obstructive pulmonary diseases%Type Ⅱ respiratory failure
目的 探讨双水平气道正压通气(BiPAP)联合舒利迭在老年中重度慢性阻塞性肺疾病(COPD)中的临床应用效果.方法 选取2012年2月至2014年4月泗水县人民医院接诊的老年COPD合并Ⅱ型呼吸衰竭患者85例作为研究对象.将其随机分为治疗组(43例)和观察组(42例,观察组给予双水平气道正压通气,吸气压力(IPAP)为13～20 cm H2O(1 cm H2O =0.098 kPa),呼气压力(EPAP)4～6 cm H2O,吸氧浓度4～6 L/min,每日早晚各1次,每次6h;治疗组在观察组的基础上给予舒利迭(50 μg/250 μg剂型)雾化吸入,每日2次.观察两个研究组治疗前后的肺功能改善情况、血气指标分析、SGRQ评分及总分变化情况.结果 治疗72 h后两组肺功能情况、血气分析情况、SGRQ评分及总分变化情况均好于治疗前,差异有统计学意义(P＜0.05).治疗组上述指标和治疗效果情况改善更为明显,差异有统计学意义(P＜0.05).结论 双水平气道正压通气与舒利迭联合治疗老年COPD合并Ⅱ型呼吸衰竭能够更好地改善患者的肺功能情况、SGRQ评分和血气分析情况,比单一采用双水平通道正压通气治疗效果更为显著,可以在临床治疗上推广使用.
目的 探討雙水平氣道正壓通氣(BiPAP)聯閤舒利迭在老年中重度慢性阻塞性肺疾病(COPD)中的臨床應用效果.方法 選取2012年2月至2014年4月泗水縣人民醫院接診的老年COPD閤併Ⅱ型呼吸衰竭患者85例作為研究對象.將其隨機分為治療組(43例)和觀察組(42例,觀察組給予雙水平氣道正壓通氣,吸氣壓力(IPAP)為13～20 cm H2O(1 cm H2O =0.098 kPa),呼氣壓力(EPAP)4～6 cm H2O,吸氧濃度4～6 L/min,每日早晚各1次,每次6h;治療組在觀察組的基礎上給予舒利迭(50 μg/250 μg劑型)霧化吸入,每日2次.觀察兩箇研究組治療前後的肺功能改善情況、血氣指標分析、SGRQ評分及總分變化情況.結果 治療72 h後兩組肺功能情況、血氣分析情況、SGRQ評分及總分變化情況均好于治療前,差異有統計學意義(P＜0.05).治療組上述指標和治療效果情況改善更為明顯,差異有統計學意義(P＜0.05).結論 雙水平氣道正壓通氣與舒利迭聯閤治療老年COPD閤併Ⅱ型呼吸衰竭能夠更好地改善患者的肺功能情況、SGRQ評分和血氣分析情況,比單一採用雙水平通道正壓通氣治療效果更為顯著,可以在臨床治療上推廣使用.
목적 탐토쌍수평기도정압통기(BiPAP)연합서리질재노년중중도만성조새성폐질병(COPD)중적림상응용효과.방법 선취2012년2월지2014년4월사수현인민의원접진적노년COPD합병Ⅱ형호흡쇠갈환자85례작위연구대상.장기수궤분위치료조(43례)화관찰조(42례,관찰조급여쌍수평기도정압통기,흡기압력(IPAP)위13～20 cm H2O(1 cm H2O =0.098 kPa),호기압력(EPAP)4～6 cm H2O,흡양농도4～6 L/min,매일조만각1차,매차6h;치료조재관찰조적기출상급여서리질(50 μg/250 μg제형)무화흡입,매일2차.관찰량개연구조치료전후적폐공능개선정황、혈기지표분석、SGRQ평분급총분변화정황.결과 치료72 h후량조폐공능정황、혈기분석정황、SGRQ평분급총분변화정황균호우치료전,차이유통계학의의(P＜0.05).치료조상술지표화치료효과정황개선경위명현,차이유통계학의의(P＜0.05).결론 쌍수평기도정압통기여서리질연합치료노년COPD합병Ⅱ형호흡쇠갈능구경호지개선환자적폐공능정황、SGRQ평분화혈기분석정황,비단일채용쌍수평통도정압통기치료효과경위현저,가이재림상치료상추엄사용.
Objective To investigate the clinical application effect of bi-level airway pressure ventilation (BiPAP) combined with seretide on elderly patients with moderate to severe chronic obstructive pulmonary diseases(COPD) with type Ⅱ respiratory failure.Methods Eighty-five patients with moderate to severe chronic obstructive pulmonary diseases combined with type Ⅱ respiratory failure from February 2012 to April 2014 were selected as the research objects.The cases were randomly divided into the treatment group (42 cases) and the control group (43 cases).Patients in observation group were given bi-level positive airway pressure ventilation,inspiratory pressure (IPAP) was 13-20 cm H2O (1 cm H2O =0.098 kPa),expiratory pressure (EPAP) was 4-6 cm H2O,oxygen concentration was 4-6 L/min,once a day each morning and evening,each time 6 h;Patients in treatment group were given seretide inhalation (50 μg/250 μg type) on the basis of observation group.The pulmonary function improved situation,blood gas analysis,SGRQ score and total score changes before and after the treatment were observed.Results After 72 hours of treatment,the pulmonary function,blood gas analysis,SGRQ score and total score changes of the two groups were better than before treatment,the difference was statistically significant (P ＜ 0.05).Compared with the treatment group,the above-mentioned indexes and therapeutic effect of improvement was more obvious in the observation group,the difference was statistically significant (P ＜ 0.05).Conclusions Bi-level airway pressure ventilation combined with seretide in the treatment of elderly patients with moderate to severe chronic obstructive pulmonary diseases with type Ⅱ respiratory failure,can better improve the patients' pulmonary function,SGRQ score and blood gas analysis.The effect is more significant than only use by bi-level airway pressure ventilation combined with seretide,can be used widely in clinical treatment.
